Filtered By:
Condition: Ischemic Stroke
Management: Marketing
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 31 results found since Jan 2013.
NICE issues final appraisal determination on apixaban for prevention of stroke and systemic embolism in non-valvular atrial fibrillation
Source: NICE
Area: News
In its final appraisal determination (FAD), NICE has supported the use of apixaban as an option for preventing stroke and systemic embolism within its marketing authorisation, that is, in people with nonvalvular atrial fibrillation with one or more risk factors (prior stroke or ischaemic attack, age 75 years or older, hypertension, diabetes mellitus or symptomatic heart failure).
The appeal period for this appraisal will close on 6 February 2013.
Source: NeLM - Cardiovascular Medicine - January 23, 2013 Category: Cardiology Source Type: news
